$HOWL
Werewolf Therapeutics, Inc. Stock $howl

$howl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000178553024000012 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$742.0K	$1.501M	$19.94M
YoY Change	-83.38%	-79.39%	21.6%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.996M	$4.814M	$18.67M
YoY Change	0.3%	4.58%	-0.14%
% of Gross Profit
Research & Development	$12.91M	$9.649M	$41.78M
YoY Change	10.27%	-39.16%	-22.29%
% of Gross Profit
Depreciation & Amortization	$464.0K	$460.0K	$1.764M
YoY Change	9.18%	10.31%	60.36%
% of Gross Profit
Operating Expenses	$17.90M	$14.46M	$60.45M
YoY Change	7.29%	-29.32%	-16.58%
Operating Profit	-$17.16M		-$40.50M
YoY Change	40.41%		-27.75%
Interest Expense	$1.003M	$965.0K	$4.277M
YoY Change	-25.54%	-18.15%	124.16%
% of Operating Profit
Other Income/Expense, Net	$969.0K	-$6.000K	-$1.142M
YoY Change	302.07%	-108.57%	-150.85%
Pretax Income	-$16.19M	-$12.00M	-$37.37M
YoY Change	35.14%	0.61%	-30.56%
Income Tax
% Of Pretax Income
Net Earnings	-$16.19M	-$12.00M	-$37.37M
YoY Change	35.14%	0.61%	-30.56%
Net Earnings / Revenue	-2182.35%	-799.67%	-187.37%
Basic Earnings Per Share	-$0.39		-$1.05
Diluted Earnings Per Share	-$0.39	-$0.33	-$1.05
COMMON SHARES
Basic Shares Outstanding	42.74M shares	36.19M shares	35.65M shares
Diluted Shares Outstanding	41.61M shares		35.65M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$139.2M	$134.3M	$134.3M
YoY Change	-5.87%	3.89%	3.89%
Cash & Equivalents	$139.2M	$134.3M	$134.3M
Short-Term Investments
Other Short-Term Assets	$2.320M	$2.677M	$2.677M
YoY Change	-4.88%	-32.35%	-32.35%
Inventory
Prepaid Expenses
Receivables	$300.0K
Other Receivables	$775.0K	$1.350M
Total Short-Term Assets	$142.3M	$138.4M	$138.4M
YoY Change	-9.12%	-1.31%	-1.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.529M	$14.85M	$14.85M
YoY Change	-13.45%	65.18%	-14.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$248.0K	$21.62M	$21.62M
YoY Change	-62.99%	1466.45%	733.35%
Total Long-Term Assets	$35.32M	$36.46M	$36.46M
YoY Change	-8.29%	81.91%	81.91%
TOTAL ASSETS
Total Short-Term Assets	$142.3M	$138.4M	$138.4M
Total Long-Term Assets	$35.32M	$36.46M	$36.46M
Total Assets	$177.6M	$174.8M	$174.8M
YoY Change	-8.96%	9.1%	9.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.594M	$1.336M	$1.336M
YoY Change	-24.31%	9.42%	9.42%
Accrued Expenses	$6.215M	$10.47M	$10.47M
YoY Change	-53.34%	-26.03%	-35.53%
Deferred Revenue	$502.0K	$907.0K
YoY Change		-86.05%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.67M	$6.667M	$6.667M
YoY Change
Total Short-Term Liabilities	$21.21M	$19.38M	$19.38M
YoY Change	-2.34%	-19.22%	-19.22%
LONG-TERM LIABILITIES
Long-Term Debt	$27.75M	$32.66M	$32.66M
YoY Change	-28.97%
Other Long-Term Liabilities	$11.05M	$11.43M	$11.43M
YoY Change		5881.68%	-17.92%
Total Long-Term Liabilities	$38.80M	$44.08M	$44.08M
YoY Change		22979.06%	216.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.21M	$19.38M	$19.38M
Total Long-Term Liabilities	$38.80M	$44.08M	$44.08M
Total Liabilities	$60.01M	$63.46M	$63.46M
YoY Change	-18.9%	67.4%	67.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$360.3M	-$344.1M
YoY Change	13.05%	12.18%
Common Stock	$4.000K	$4.000K
YoY Change	33.33%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$117.6M	$111.4M	$111.4M
YoY Change
Total Liabilities & Shareholders Equity	$177.6M	$174.8M	$174.8M
YoY Change	-8.96%	9.1%	9.1%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$16.19M	-$12.00M	-$37.37M
YoY Change	35.14%	0.61%	-30.56%
Depreciation, Depletion And Amortization	$464.0K	$460.0K	$1.764M
YoY Change	9.18%	10.31%	60.36%
Cash From Operating Activities	-$15.30M	-$4.585M	-$32.61M
YoY Change	54.55%	-61.37%	-19.67%
INVESTING ACTIVITIES
Capital Expenditures	$111.0K	$198.0K	$769.0K
YoY Change	-33.93%	-61.78%	-78.7%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$111.0K	-$198.0K	-$769.0K
YoY Change	-33.93%	-61.78%	-78.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$18.43M
YoY Change			13.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$20.26M	9.073M	58.43M
YoY Change	-58.33%	622.37%	267.34%
NET CHANGE
Cash From Operating Activities	-$15.30M	-4.585M	-32.61M
Cash From Investing Activities	-$111.0K	-198.0K	-769.0K
Cash From Financing Activities	$20.26M	9.073M	58.43M
Net Change In Cash	$4.851M	4.290M	25.05M
YoY Change	-87.42%	-138.54%	-188.51%
FREE CASH FLOW
Cash From Operating Activities	-$15.30M	-$4.585M	-$32.61M
Capital Expenditures	$111.0K	$198.0K	$769.0K
Free Cash Flow	-$15.41M	-$4.783M	-$33.38M
YoY Change	53.07%	-61.39%	-24.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40366
CY2023	dei	Entity Registrant Name EntityRegistrantName	WEREWOLF THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3523180
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Talcott Ave
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	952‑0555
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37368000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-53810000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2246000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.86
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001785530
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Trading Symbol TradingSymbol	HOWL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	67355166	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42737191	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134343000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129315000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2677000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3957000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1350000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6928000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	138370000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	140200000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7958000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8988000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	21023000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1214000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6888000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8463000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	594000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1380000	usd
CY2023Q4	us-gaap	Assets Assets	174833000	usd
CY2022Q4	us-gaap	Assets Assets	160245000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1336000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1221000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8860000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14152000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1608000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2084000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	907000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6532000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6667000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19378000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23989000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10992000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12600000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	433000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1128000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	32656000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	191000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	63459000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	37908000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39107048	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31515074	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39107048	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31433731	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455443000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	429039000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344073000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306705000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	111374000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	122337000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174833000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	160245000	usd
CY2023	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	19943000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	16401000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41776000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53761000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18670000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18696000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	60446000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	72457000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40503000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-56056000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1908000	usd
CY2023	us-gaap	Interest Expense InterestExpense	3139000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1142000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	338000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3135000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.86
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35646572	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35646572	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28863935	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28863935	shares
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7400000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	224000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-53810000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	122337000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	93000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8008000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37368000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	111374000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37368000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-53810000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	8008000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7400000	usd
CY2023	us-gaap	Depreciation Depreciation	1764000	usd
CY2022	us-gaap	Depreciation Depreciation	1104000	usd
CY2023	howl	Non Cash Interest Expense NonCashInterestExpense	273000	usd
CY2022	howl	Non Cash Interest Expense NonCashInterestExpense	0	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1575000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1406000	usd
CY2023	howl	Change In Fair Value Of Success Payment Liability ChangeInFairValueOfSuccessPaymentLiability	-1030000	usd
CY2022	howl	Change In Fair Value Of Success Payment Liability ChangeInFairValueOfSuccessPaymentLiability	555000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	60000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	203000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1267000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	262000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5578000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	6928000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-4335000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	3046000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6320000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7660000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2084000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-977000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32612000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40596000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	769000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3611000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-769000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3611000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18329000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15740000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	40000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	93000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	254000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	88000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58429000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15906000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25048000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-28301000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130529000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	155577000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130529000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134343000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129315000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	211000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	21023000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1214000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	155577000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130529000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2556000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	76000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	111000	usd
CY2023	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	36000	usd
CY2022	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	4000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134300000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	operating_segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, those related to revenue recognition, accrued expenses, assumptions used in the valuation of stock-based compensation expense and income taxes. Actual results could differ from those estimates.</span></div>
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	21200000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2023	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	19900000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	16400000	usd
CY2023	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	4200000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. Cash and cash equivalents are primarily held with three reputable financial institutions in the United States. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.
CY2023Q4	howl	Concentrations Of Credit Risk Number Of Financial Institutions ConcentrationsOfCreditRiskNumberOfFinancialInstitutions	3	institution
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7660000	usd
CY2023	howl	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	5000000	usd
CY2023	howl	Contract With Customer Liability Reductions ContractWithCustomerLiabilityReductions	11320000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1340000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7660000	usd
CY2023	howl	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	5000000	usd
CY2023	howl	Contract With Customer Liability Reductions ContractWithCustomerLiabilityReductions	11320000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1340000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022	howl	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	15000000	usd
CY2022	howl	Contract With Customer Liability Reductions ContractWithCustomerLiabilityReductions	7340000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7660000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022	howl	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	15000000	usd
CY2022	howl	Contract With Customer Liability Reductions ContractWithCustomerLiabilityReductions	7340000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7660000	usd
CY2023	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	6700000	usd
CY2022	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	0	usd
CY2023Q2	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	170000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8860000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14152000	usd
CY2023Q2	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11128000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10394000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	3170000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	1406000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7958000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8988000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3627000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3135000	usd
CY2023Q4	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	2772000	usd
CY2022Q4	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	6674000	usd
CY2023Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	1049000	usd
CY2022Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	2990000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	655000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	613000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	310000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2023Q4	howl	Success Payment Liability SuccessPaymentLiability	0	usd
CY2022Q4	howl	Success Payment Liability SuccessPaymentLiability	570000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	447000	usd
CY2022Q2	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.045
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6667000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	20000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	13333000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	40000000	usd
CY2023Q2	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
CY2023Q2	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8539247	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6808337	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8008000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7400000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	9900000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2442000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2537000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1210000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	837000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	228000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	1562000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	834000	usd
CY2023	us-gaap	Lease Cost LeaseCost	2090000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2768000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3000000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2100000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2505000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2337000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2403000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2471000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2542000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3716000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15974000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3374000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12600000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.094
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.083
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.124
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.304
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.045
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.024
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.030
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.015
CY2023	howl	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.006
CY2022	howl	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.002
CY2023	howl	Effective Income Tax Rate Reconciliation Net Operating Income Loss Adjustments EffectiveIncomeTaxRateReconciliationNetOperatingIncomeLossAdjustments	-0.202
CY2022	howl	Effective Income Tax Rate Reconciliation Net Operating Income Loss Adjustments EffectiveIncomeTaxRateReconciliationNetOperatingIncomeLossAdjustments	0.000
CY2023	howl	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	0.013
CY2022	howl	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	0.000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23873000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26234000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3168000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3819000	usd
CY2023Q4	howl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	3645000	usd
CY2022Q4	howl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	4180000	usd
CY2023Q4	howl	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	95000	usd
CY2022Q4	howl	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	103000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1295000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	950000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2021000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1448000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16162000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9474000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50259000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46208000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47058000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42417000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3201000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3791000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1993000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2358000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1208000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1433000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3201000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3791000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	howl	Capitalized Research And Experimentation Expenses CapitalizedResearchAndExperimentationExpenses	27900000	usd
CY2022	howl	Capitalized Research And Experimentation Expenses CapitalizedResearchAndExperimentationExpenses	36100000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4600000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-16300000	usd
CY2023Q4	howl	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	96500000	usd
CY2023	howl	Sublease Cash Payments Received SubleaseCashPaymentsReceived	1600000	usd
CY2022	howl	Sublease Cash Payments Received SubleaseCashPaymentsReceived	800000	usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	200000	usd
CY2023Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	200000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6143085	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5736425	shares

Files In Submission

Name	View Source	Status
0001785530-24-000012-index-headers.html	Edgar Link	pending
0001785530-24-000012-index.html	Edgar Link	pending
0001785530-24-000012.txt	Edgar Link	pending
0001785530-24-000012-xbrl.zip	Edgar Link	pending
a12312023ex1022.htm	Edgar Link	pending
a12312023ex231.htm	Edgar Link	pending
a12312023ex311.htm	Edgar Link	pending
a12312023ex312.htm	Edgar Link	pending
a12312023ex321.htm	Edgar Link	pending
a12312023ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
howl-20231231.htm	Edgar Link	pending
howl-20231231.xsd	Edgar Link	pending
howl-20231231_g1.jpg	Edgar Link	pending
howl-20231231_g2.jpg	Edgar Link	pending
howl-20231231_g3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
howl-20231231_cal.xml	Edgar Link	unprocessable
howl-20231231_def.xml	Edgar Link	unprocessable
howl-20231231_lab.xml	Edgar Link	unprocessable
howl-20231231_pre.xml	Edgar Link	unprocessable
howl-20231231_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOWL
Werewolf Therapeutics, Inc. Stock $howl

2024 Q1 Form 10-K Financial Statement

#000178553024000012 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL Werewolf Therapeutics, Inc. Stock $howl

2024 Q1 Form 10-K Financial Statement

#000178553024000012 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL
Werewolf Therapeutics, Inc. Stock $howl